2025-09-11 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the provided data.

**Report: Natera Inc. (NTRA) Analysis**

Natera Inc. is a genetic testing company focused on reproductive health, oncology, and organ health.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (NTRA):** 171.88%
*   **Cumulative Return (VOO):** 39.61%
*   **Absolute Outperformance:** 132.27%
*   **Relative Outperformance Position:** 14.6% (Indicates NTRA's outperformance is near the lower end of its historical range compared to VOO.)

**Analysis:** NTRA has significantly outperformed the S&P 500. However, the relative outperformance position suggests that the current outperformance is less pronounced compared to its historical trends.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2015-2017  | -6.0%  | 62.4%  | -6.0%   | 1.0   | 1.2    |
| 2016-2018  | 29.0%  | 80.1%  | 29.0%   | 1.0   | 1.8    |
| 2017-2019  | 159.0% | 80.1%  | 159.0%  | 1.0   | 4.5    |
| 2018-2020  | 530.0% | 80.1%  | 530.0%  | 1.0   | 13.2   |
| 2019-2021  | 355.0% | 62.9%  | 355.0%  | -0.0  | 12.3   |
| 2020-2022  | -119.0%| 62.9%  | -108.0% | -0.1  | 5.3    |
| 2021-2023  | -482.0%| 69.9%  | -492.0% | -0.1  | 8.3    |
| 2022-2024  | -75.0% | 70.6%  | -105.0% | -0.1  | 20.9   |
| 2023-2025  | 121.0% | 76.1%  | 75.0%   | -0.0  | 23.3   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Demonstrates significant volatility.  High growth periods (e.g., 2018-2020) are followed by substantial declines (e.g., 2021-2023). Recent showing positive growth(2023-2025).
*   **MDD (Maximum Drawdown):**  Indicates substantial risk, with drawdowns consistently high.
*   **Alpha:**  Shows periods of significant outperformance (positive alpha) and underperformance (negative alpha) relative to the benchmark.
*   **Beta:**  Beta values are near 0 or 1.0, suggesting that NTRA's price movements are less correlated or correlated with the market.
*   **Cap(B):** Market Cap in Billions is showing increase trend.

**2. Recent Price Action**

*   **Current Price:** 176.37
*   **Last Market Data:** Price: 169.79, Previous Close: 176.37, Change: -3.73 (Indicates a recent price decrease)
*   **5-Day Moving Average:** 169.17
*   **20-Day Moving Average:** 164.54
*   **60-Day Moving Average:** 156.97

**Analysis:** The price is above all moving averages, suggesting an upward trend. The recent price decrease and price closing under 5-Day moving average may signal a potential short-term correction or consolidation. The change of -3.73 indicates a notable negative movement.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 73.61 (Overbought territory, suggesting potential for a pullback)
*   **PPO:** 0.318 (Positive, indicates an upward trend)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta Relative Divergence:** 0.0 (Indicates a short-term downtrend)
*   **Expected Return:** 113.0% (Long-term expected outperformance vs. S&P 500)

**Analysis:** The MRI indicates a low risk, but the RSI suggests the stock is overbought. The hybrid signal recommends buying 80% of cash. The negative change in relative divergence supports the short-term downward trend indicated by the recent price action. The high expected return suggests optimism for long-term growth.

**4. Recent News & Significant Events**

*   **Why Natera (NTRA) Shares Are Falling Today (StockStory):** Explains potential reasons for the recent price drop.
*   **3 Reasons We’re Fans of Natera (NTRA) (StockStory):** Presents positive aspects of the company.
*   **Natera (NTRA): How the ARCHER Trial May Shape Future Valuation After Key Signatera Milestone (Simply Wall St.):** Highlights the importance of clinical trials for future valuation.
*   **Liquid Biopsy Market Trends and Industry Forecast to 2030 (GlobeNewswire):** Positive outlook for the overall market Natera operates in.
*   **Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics (Insider Monkey):** Legal updates can impact investor sentiment.
*   **Health Care Roundup: Market Talk (The Wall Street Journal):** General industry news.

**Analysis:** Recent news presents a mixed picture. While some articles highlight positive aspects of Natera and its market, others explain the current stock decline and discuss potential risks. Intellectual property litigation is also a factor to consider.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.45)
*   **Target Price:** Average: 198.45, High: 268.00, Low: 37.00

**Analysis:**  Analyst sentiment is strongly positive, with a "Strong Buy" consensus and an average target price significantly above the current price. The wide range in target prices (37.00 to 268.00) indicates uncertainty or differing opinions on the stock's potential.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출       |
|--------------|--------|------------|
| 2025-08-08   | -0.74  | 0.55 B$   |
| 2025-05-09   | -0.5   | 0.50 B$   |
| 2024-11-12   | -0.26  | 0.44 B$   |
| 2024-08-09   | -0.3   | 0.41 B$   |
| 2025-08-08   | -0.3   | 0.41 B$   |

**Analysis:**

*   **EPS (Earnings Per Share):**  Consistently negative, indicating the company is not yet profitable.
*   **Revenue:** Shows an increasing trend, suggesting growth in the company's business.

**6. Financial Information**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $1.25B  | -8.10%   |
| 2025-03-31 | $1.24B  | -5.40%   |
| 2024-12-31 | $1.20B  | -4.50%   |
| 2024-09-30 | $0.88B  | -3.60%   |
| 2024-06-30 | $0.84B  | -4.48%   |

**Analysis:**

*   **Revenue:**  Consistent growth in revenue quarter over quarter.
*   **Profit Margin:**  High and increasing profit margins indicate good cost control and pricing power.
*   **Equity:** Increasing equity suggests strengthening financial position.
*   **ROE (Return on Equity):** Negative ROE reflects the company's current lack of profitability. However, the trend is moving towards less negative, indicating improvement.

**7. Overall Summary**

Natera (NTRA) is a high-growth, yet currently unprofitable, company in the genetic testing space. It has significantly outperformed the S&P 500 in the past, but its recent performance is more mixed.

**Key Positives:**

*   Strong revenue growth and high profit margins.
*   Positive analyst sentiment and high target prices.
*   Increasing equity.
*   High expected return (long-term).
*   Low market risk indicator.

**Key Negatives/Risks:**

*   Currently unprofitable with negative EPS and ROE.
*   High historical volatility and maximum drawdowns.
*   Recent price decrease and overbought RSI signal potential for pullback.
*   Intellectual property litigation adds uncertainty.
*   Recent negative news headlines.
*   Relatively less outperformance recently compared to its historical trends.

**Conclusion:**

NTRA presents a high-risk, high-reward investment opportunity. The company's growth prospects, as indicated by revenue growth and analyst optimism, are promising. However, investors should be aware of the risks associated with its current lack of profitability, high volatility, and ongoing legal challenges. The recent pullback in price and mixed news sentiment warrant caution in the short term. Long-term investors should monitor the company's progress towards profitability and the outcome of its clinical trials and legal battles.
